G R Pasternack
Overview
Explore the profile of G R Pasternack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kadkol S, El Naga G, Brody J, Bai J, Gusev Y, Dooley W, et al.
Breast Cancer Res Treat
. 2001 Oct;
68(1):65-73.
PMID: 11678310
The pp32 gene family consists of at least three closely related members, pp32, pp32r1 and pp32r2. In spite of a high degree of identity at the nucleotide level, pp32 functionally...
2.
Bai J, Brody J, Kadkol S, Pasternack G
Oncogene
. 2001 May;
20(17):2153-60.
PMID: 11360199
Alternative use of genes of the closely-related pp32 family is a common occurrence in human prostate cancer. pp32r1 and pp32r2, the oncogenic members of the pp32 family, are expressed in...
3.
Kadkol S, Gage W, Pasternack G
Mol Diagn
. 1999 Dec;
4(3):169-83.
PMID: 10553018
In situ hybridization is a technique to determine and localize target nucleic acids in morphologically preserved tissue sections. Recent advances in methods have greatly increased the sensitivity of the technique,...
4.
Brody J, Kadkol S, Mahmoud M, Rebel J, Pasternack G
J Biol Chem
. 1999 Jul;
274(29):20053-5.
PMID: 10400610
Oncogenic potential in prostate cancer is modulated in part by alternative use of genes of the pp32 family. This family includes the tumor suppressor pp32, expressed in normal tissue, and...
5.
Kadkol S, Brody J, Pevsner J, Bai J, Pasternack G
Nat Med
. 1999 Mar;
5(3):275-9.
PMID: 10086381
Only a small percentage of primary prostate cancers have genetic changes. In contrast, nearly 90% of clinically significant human prostate cancers seems to express high levels of the nuclear phosphoprotein...
6.
Milgraum L, Witters L, Pasternack G, Kuhajda F
Clin Cancer Res
. 1998 Nov;
3(11):2115-20.
PMID: 9815604
Expression of high levels of fatty acid synthase (FAS), an important enzyme in fatty acid synthesis, has been identified in a wide variety of human carcinomas. In breast and prostate...
7.
Pizer E, Lax S, Kuhajda F, Pasternack G, Kurman R
Cancer
. 1998 Aug;
83(3):528-37.
PMID: 9690546
Background: Fatty acid synthase (FAS), a biosynthetic enzyme, normally functions in the liver to convert dietary carbohydrate to fat, but it is minimally expressed in most other normal adult tissues....
8.
Kadkol S, Brody J, Epstein J, Kuhajda F, Pasternack G
Prostate
. 1998 Mar;
34(3):231-7.
PMID: 9492852
Background: pp32 is a differentiation-regulated nuclear phosphoprotein that is highly expressed in many cancers, but is restricted to self-renewing and long-lived normal cell populations. During murine embryogenesis, pp32 is expressed...
9.
Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia
Rashid A, Pizer E, Moga M, Milgraum L, Zahurak M, Pasternack G, et al.
Am J Pathol
. 1997 Jan;
150(1):201-8.
PMID: 9006336
Expression of the primary enzyme catalyzing the synthesis of fatty acids, ie, fatty acid synthase (FAS), and ex vivo fatty acid synthetic activity were examined in colorectal epithelium and neoplasms,...
10.
Pizer E, Kurman R, Pasternack G, Kuhajda F
Int J Gynecol Pathol
. 1997 Jan;
16(1):45-51.
PMID: 8986532
Estrogen-driven proliferative phase growth is the most rapid physiological proliferative process that occurs in the adult. The tissue growth that occurs during this phase of the menstrual cycle requires incorporation...